ストックスクリーナーアプリを入手
249.89
0.45%
1.10
前日終値:
$248.79
開ける：
$247.46
24時間の取引高:
120.30K
Relative Volume:
0.15
時価総額：
$32.09B
収益：
$2.09B
当期純損益:
$-332.26M
株価収益率:
-60.36
EPS:
-4.14
ネットキャッシュフロー:
$16.06M
1週間 パフォーマンス:
-3.11%
1か月 パフォーマンス:
-14.42%
6か月 パフォーマンス:
+67.02%
1年 パフォーマンス:
+52.68%
1日の値動き範囲:
$246.26
$250.71
1週間の範囲:
$229.85
$254.17
52週間の値動き範囲:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ALNY | 249.89 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| VRTX | 448.37 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.56 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| BNTX | 103.28 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Lifted by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Banque Cantonale Vaudoise Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Victory Capital Management Inc. Has $11.80 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Empowered Funds LLC Buys 5,362 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Biodefense Market to Witness Huge Growth by 2031: Achaogen Inc., - openPR
Alnylam Pharmaceuticals' (ALNY) Outperform Rating Reiterated at William Blair - MarketBeat
Jefferies Taps Former Alnylam CEO Maraganore as Senior Adviser - BNN Bloomberg
Old drugs shed new light on a rare skin disease - Drug Discovery News
10 Biggest Biotechnology Companies - Investopedia
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Piper Sandler Reiterates Overweight Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis - Seeking Alpha
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by LMR Partners LLP - MarketBeat
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment - Clinical Trials Arena
Alnylam's Nucresiran Achieves 96% TTR Reduction in Phase 1 ATTR Amyloidosis Trial | ALNY Stock News - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $294.50 Consensus Price Target from Analysts - MarketBeat
Alnylam Pharmaceuticals Enters Oversold Territory (ALNY) - Nasdaq
Primary Hyperoxaluria Treatment Market Outlook by Examining - openPR
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 23.6% in October - MarketBeat
Alnylam Says It's Not A 'Patent Troll' In Vax IP Row - Law360
FMR LLC Expands Stake in Alnylam Pharmaceuticals - GuruFocus.com
Alnylam downgraded at Wolfe on doubts over Amvuttra growth - MSN
Alnylam Pharmaceuticals To Present At UBS Global Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq
Baillie Gifford & Co. Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wolfe Research - MarketBeat
Los Angeles Capital Management LLC Has $37.68 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Trading (ALNY) With Integrated Risk Controls - Stock Traders Daily
5,283 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by New York State Teachers Retirement System - MarketBeat
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks - Benzinga
Wellington Management Group LLP's Strategic Reduction in Alnylam Pharmaceuticals Inc - GuruFocus.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Increased by AIA Group Ltd - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of Alaska Department of Revenue - MarketBeat
What is HC Wainwright's Forecast for ALNY FY2024 Earnings? - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
An RNAi renaissance is creating a new generation of startups - BioPharma Dive
Upcoming Opportunities in Hereditary Amyloidosis Market: - openPR
Asset Management One Co. Ltd. Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Van ECK Associates Corp Sells 3,539 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Hemoglobinopathies Market Growth Analysis: Industry - openPR
Alnylam's SWOT analysis: biotech stock poised for growth in ATTR-CM market - Investing.com
Alnylam launches Phase 1 trial of ALN-HTT02 for Huntington’s - Huntington's Disease News
New York State Common Retirement Fund Sells 3,724,457 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. Promotes Cynthia Clayton to Vice President of Investor Relations and Corporate Communications - Marketscreener.com
Alnylam shares remain Buy-rated at H.C. Wainwright, target held steady amid ATTR-CM updates - Investing.com UK
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Boosted by Wealth Enhancement Advisory Services LLC - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results - MarketBeat
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - MSN
Silvant Capital Management LLC Has $4.45 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Aug 20 '24 |
Sale |
280.00 |
15,000 |
4,200,000 |
73,441 |
0.82%
0.27%
大文字化:
|
ボリューム (24 時間):